Compare ASST & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASST | EYPT |
|---|---|---|
| Founded | 2020 | 1987 |
| Country | United States | United States |
| Employees | 28 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2022 | 2005 |
| Metric | ASST | EYPT |
|---|---|---|
| Price | $18.16 | $12.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $23.50 | ★ $31.80 |
| AVG Volume (30 Days) | ★ 3.3M | 724.3K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $633,489.00 | ★ $7,539,000.00 |
| Revenue This Year | $294.91 | N/A |
| Revenue Next Year | $12.16 | $3,115.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 128.67 | N/A |
| 52 Week Low | $0.49 | $5.57 |
| 52 Week High | $18.54 | $19.11 |
| Indicator | ASST | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 63.09 | 46.70 |
| Support Level | $14.31 | $12.66 |
| Resistance Level | N/A | $14.73 |
| Average True Range (ATR) | 1.30 | 0.74 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 69.09 | 47.26 |
Strive Inc is a structured finance company and institutional asset manager focused on disciplined capital allocation and long term value creation. The company has adopted bitcoin as its hurdle rate for capital deployment because of its fiduciary duty to maximize long-term value for stockholders, and compounding purchasing power over time. It operates in two reportable operating segments: the Asset Management segment, which provides investment advisory services and the Corporate & Other segment, which includes the company's bitcoin treasury operations. The majority of the revenue is derived from the Asset Management segment.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.